-
Recent Posts
- Cortico–reticulo–spinal circuit reorganization enables functional recovery after severe spinal cord contusion
- Serotonin receptor and dendritic plasticity in the spinal cord mediated by chronic serotonergic pharmacotherapy combined with exercise following complete SCI in the adult rat
- Enabling hand function in chronic spinal cord injury patients with non-invasive transcutaneous stimulation and buspirone: A double-blinded, sham controlled pilot study
- Linking axon transport to regeneration using in vitro laser axotomy
- Gene jumpstarts regeneration of damaged nerve cells
- UCLA researchers find a way to repair nerve damage with stem cells
- Closed-loop neuromodulation restores network connectivity and motor control after spinal cord injury
- Development of an intraneural peripheral stimulation paradigm for reversing hand paralysis in non-human primates
- Paraplegic rats walk again after therapy, now we know why
- Chondroitinase improves anatomical and functional outcomes after primate spinal cord injury
- Spinal Cord Injury Research: Mayo Clinic Radio
- Reducing Pericyte-Derived Scarring Promotes Recovery after Spinal Cord Injury
- Revolutionary Robotic Treatment (HAL)For Patients With Spinal Cord Injuries Now Available In United States
- Restorative effects of human neural stem cell grafts on the primate spinal cord
- Improving Arm and Hand Function after Spinal Cord Injury
Host of Working 2 Walk Annual Symposium
Follow on Twitter
My TweetsSpinal Cord Injury Research and Science at Facebook
Archives
Tag Archives: Jan-Eric Ahlfors
Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders
(Newswire.com) Press Release: November 8, 2017 Fortuna Fix – Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming … Continue reading
Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
Montreal, Canada, May 4, 2017 (Newswire.com) – Fortuna Fix Inc. (“Fortuna”), a private, clinical-stage biotech company, is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat … Continue reading
Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Rehabilitation, Spinal Research, Stem Cell Research, Unite 2 Fight Paralysis
Tagged Jan-Eric Ahlfors, MPH; and Professor James Giordano, PhD; Col. (R) Dallas Hack, PhD; Father Kevin FitzGerald, Professor Michael Fehlings
1 Comment
New World Laboratories pushes forward with clinical trial
New World Laboratories acts as its own research center, allowing it to create its own therapeutic platforms. The company focuses its efforts on three main sectors—therapeutic drugs, medical devices, and cell therapies. For example, the apoptosis program (programmed cell death) … Continue reading
